Trince

Ottergemsesteenweg-Zuid 731

9000 Gent

BE

Trince

Foundation date

17/09/2021

Sector

#Supplier & Engineering

Subsector

Trince, a spin-off company from UGent is dedicated to delivering molecules into cells, both in vitro and ex vivo. Its LumiPore transfection platform combines laser exposure and nanoparticles to transiently permeabilize cell membranes. It can be used to deliver a wide variety of effector molecules into virtually any cell type, including hard-to-transfect cells. The high-throughput technology ensures efficient and gentle transfection, maximizing the therapeutic quality of the final cell product.

Upcoming events

Latest news

  • Celyad Oncology appoints Georges Rawadi as its new CEO

    Tuesday March 28th 2023

  • BioLizard appoints Paul Vauterin as Chief Technology Officer

    Monday March 27th 2023

  • ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI

    Monday March 27th 2023